LuSeed Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

LuSeed General Information

Description

Developer of a medical device for brain aneurysm treatment designed to provide a minimally invasive, single-implant intervention. The company offers a dual-layer braided mesh design, angle-agnostic deployment, and minimal protrusion into parent arteries, enabling neurointerventional physicians to treat aneurysm patients more safely and with reduced reliance on strong blood thinners, making it more suitable for ruptured cases.

Contact Information

Website
www.luseed-vascular.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Yitzhak Rabin 1
  • Global Towers
  • Petach Tikva
  • Israel
+972
Primary Industry
Surgical Devices
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Yitzhak Rabin 1
  • Global Towers
  • Petach Tikva
  • Israel
+972

LuSeed Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LuSeed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 25-Jan-2025 Completed Generating Revenue
6. Later Stage VC 31-Oct-2024 Completed Generating Revenue
5. Accelerator/Incubator 12-May-2024 Completed Generating Revenue
4. Later Stage VC (Series A) 16-Nov-2023 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2021 Completed Clinical Trials - General
2. Seed Round 01-Jan-2020 $5.1M $6.1M Completed Clinical Trials - General
1. Accelerator/Incubator 28-Nov-2018 $1M $1M Completed Clinical Trials - General
To view LuSeed’s complete valuation and funding history, request access »

LuSeed Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preferred A1
Preferred A
Ordinary A 40,800 $2.55 $2.55 1x $2.55 15.23%
To view LuSeed’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

LuSeed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a medical device for brain aneurysm treatment designed to provide a minimally invasive, single-implant inte
Surgical Devices
Petach Tikva, Israel
17 As of 2026

Minneapolis, MN
 

Portage, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LuSeed Competitors (3)

One of LuSeed’s 3 competitors is Medtronic, a Corporation company based in Minneapolis, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Medtronic Corporation Minneapolis, MN
Stryker Formerly VC-backed Portage, MI
Kenvue Canada Corporation Markham, Canada
You’re viewing 3 of 3 competitors. Get the full list »

LuSeed Patents

  • 14

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

LuSeed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024502376-A Endovascular device Pending 10-Jan-2021
EP-4274494-A1 Intravascular device Pending 10-Jan-2021
EP-4274494-A4 Intravascular device Pending 10-Jan-2021
US-20230346382-A1 Intravascular device Pending 10-Jan-2021
US-20250134526-A1 Intravascular device Pending 10-Jan-2021 A61B17/12113
To view LuSeed’s complete patent history, request access »

LuSeed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LuSeed Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
GlenRock Israel Growth/Expansion Minority
Global Support Capital Family Office Minority
SHAAR Accelerator/Incubator
Creative Destruction Lab Accelerator/Incubator
Gandyr Investments Family Office Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

LuSeed FAQs

  • When was LuSeed founded?

    LuSeed was founded in 2017.

  • Where is LuSeed headquartered?

    LuSeed is headquartered in Petach Tikva, Israel.

  • What is the size of LuSeed?

    LuSeed has 17 total employees.

  • What industry is LuSeed in?

    LuSeed’s primary industry is Surgical Devices.

  • Is LuSeed a private or public company?

    LuSeed is a Private company.

  • What is LuSeed’s current revenue?

    The current revenue for LuSeed is .

  • How much funding has LuSeed raised over time?

    LuSeed has raised $9.6M.

  • Who are LuSeed’s investors?

    GlenRock Israel, Global Support Capital, SHAAR, Creative Destruction Lab, and Gandyr Investments are 5 of 6 investors who have invested in LuSeed.

  • Who are LuSeed’s competitors?

    Medtronic, Stryker, and Kenvue Canada are competitors of LuSeed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process